Gastrointestinal involvement in patients with chronic lymphocytic leukemia.

abstract：:Infants less than 1 year of age at diagnosis of acute lymphoblastic leukemia (ALL) have a poor prognosis, which has been attributed primarily to a breakpoint in chromosomal band 11q23 or the MLL gene. Most infants with an 11q23 breakpoint have a t(4;11)(q21 ;q23). We studied the cytogenetics of the leukemia cells of 5...

journal_title：Leukemia

authors： Heerema NA,Sather HN,Ge J,Arthur DC,Hilden JM,Trigg ME,Reaman GH

更新日期：1999-05-01 00:00:00

abstract：:Reduced-intensity conditioning (RIC) regimens have been increasingly used as an alternative to conventional myeloablative conditioning (MAC) regimens for elderly patients, for patients medically infirm to qualify for conventional allogeneic stem cell transplantation (SCT), and for disorders in which traditional MAC-SC...

journal_title：Leukemia

authors： Jiménez M,Ercilla G,Martínez C

更新日期：2007-08-01 00:00:00

abstract：:Injection of a dual tropic virus (DTV) isolated from a T cell lymphoma AKR/J mice into the thymus of 14 day old AKR/J puppies accelerates lymphoma development; 90-100% of the injected mice develop the disease within 120 days. In contrast a cell free centrifuge CFC-666 prepared B cell lymphoma of AKR/J origin injected ...

journal_title：Leukemia

authors： Peled A,Haran-Ghera N

更新日期：1988-12-01 00:00:00

abstract：:FMS-like tyrosine kinase 3 (FLT3) is a transmembrane protein expressed on normal hematopoietic stem and progenitor cells (HSC) and retained on malignant blasts in acute myeloid leukemia (AML). We engineered CD8+ and CD4+ T-cells expressing a FLT3-specific chimeric antigen receptor (CAR) and demonstrate they confer pot...

journal_title：Leukemia

authors： Jetani H,Garcia-Cadenas I,Nerreter T,Thomas S,Rydzek J,Meijide JB,Bonig H,Herr W,Sierra J,Einsele H,Hudecek M

更新日期：2018-05-01 00:00:00

abstract：:The pleiotropic cytokines, interleukin (IL)-1 alpha, type I interferons and IL-6 also act on cells involved in antibody production. Somehow the immunologic tolerance to these cytokines is often spontaneously broken--even in healthy individuals. Thus, relatively high concentrations of high affinity IgG antibodies again...

journal_title：Leukemia

authors： Hansen MB,Svenson M,Diamant M,Abell K,Bendtzen K

更新日期：1995-07-01 00:00:00

abstract：:We explored the relationship between time to relapse and different exposure variables (serum methotrexate (S-MTX) 23, 36 and 42 h after start of administration, MTX elimination time and leucovorin (LV) dose) during high-dose MTX (HDM) treatment of 445 children with acute lymphoblastic leukemia. MTX was infused at 5 g/...

journal_title：Leukemia

authors： Skärby TV,Anderson H,Heldrup J,Kanerva JA,Seidel H,Schmiegelow K,Nordic Society of Paediatric Haematology and Oncology (NOPHO).

更新日期：2006-11-01 00:00:00

abstract：:Abnormal karyotypes are common in cancer cells and frequently observed in acute myeloid leukemia (AML), in which complex karyotype aberrations are associated with poor prognosis. How exactly abnormal karyotypes arise and are propagated in AML is unclear. TP53 mutations and deletions are frequent in complex karyotype A...

journal_title：Leukemia

authors： Cazzola A,Schlegel C,Jansen I,Bochtler T,Jauch A,Krämer A

更新日期：2019-11-01 00:00:00

abstract：:Malignant cells of patients with cutaneous T cell lymphoma (CTCL) are of monoclonal origin and of the CD4+/CD45RO+ subset. Since unlike their normal counterparts, triggering of their TCR/CD3 in vitro elicits only a weak mitogenic response, we set out to determine which of the signal transduction molecules initiated by...

journal_title：Leukemia

authors： Fargnoli MC,Edelson RL,Berger CL,Chimenti S,Couture C,Mustelin T,Halaban R

更新日期：1997-08-01 00:00:00

abstract：:A patient with Philadelphia positive (Ph'+) acute lymphoblastic leukemia (ALL), in remission for over 4 years, developed an acute myeloblastic leukemia (AML), M2-type. During the second disease, the blast cells displayed a typical t(8;21)(q22;q22) translocation, in the absence of the Ph' chromosome. This is the first ...

journal_title：Leukemia

authors： De Cuia MR,Alimena G,Gastaldi R,Spiriti MA,Giona F,Mancini M,Mandelli F

更新日期：1989-04-01 00:00:00

abstract：:The main reason for the unfavorable clinical outcome of BCR-ABL1-positive acute lymphoblastic leukemia (ALL) is genetic instability. However, how normal B-cell precursors acquire the genetic changes that lead to transformation has not yet been completely defined. We investigated the expression of the activation-induce...

journal_title：Leukemia

authors： Iacobucci I,Lonetti A,Messa F,Ferrari A,Cilloni D,Soverini S,Paoloni F,Arruga F,Ottaviani E,Chiaretti S,Messina M,Vignetti M,Papayannidis C,Vitale A,Pane F,Piccaluga PP,Paolini S,Berton G,Baruzzi A,Saglio G,Baccar

更新日期：2010-01-01 00:00:00

abstract：:MUM1 (multiple myeloma oncogene 1)/IRF4 (interferon regulatory factor 4) is a transcription factor that is activated as a result of t(6;14)(p25;q32) in multiple myeloma. MUM1 expression is seen in various B-cell lymphomas and predicts an unfavorable outcome in some lymphoma subtypes. To elucidate its role in B-cell ma...

journal_title：Leukemia

authors： Uranishi M,Iida S,Sanda T,Ishida T,Tajima E,Ito M,Komatsu H,Inagaki H,Ueda R

更新日期：2005-08-01 00:00:00

abstract：:Chimeric antigen receptor (CAR) T cell therapies lead to high clinical response rates in B cell malignancies, and are under investigation for treatment of solid tumors. While high systemic interleukin- (IL-) 6 levels are associated with clinical cytokine release syndrome (CRS), the role of IL-6 trans-signaling within ...

journal_title：Leukemia

authors： Jiang Z,Liao R,Lv J,Li S,Zheng D,Qin L,Wu D,Chen S,Long Y,Wu Q,Wang S,Lin S,Huang X,Tang Z,Shi P,Zhou H,Liu Q,Zhao R,Li Y,Jie Y,Wei W,Lai P,Du X,Cui S,Weinkove R,Liu P,Pei D,Yao Y,Li P

更新日期：2020-11-09 00:00:00

abstract：:We explored the association between bone marrow plasma cells (BMPCs) and disease presentation and outcome among 1574 AL patients. Three BMPC groups were formulated: <5% (n = 231, 15% of study population), 5-19% (n = 1045, 66%), and ≥20% (n = 298, 19%). Heart and renal involvement were more and less prevalent, respecti...

journal_title：Leukemia

authors： Muchtar E,Gertz MA,Kourelis TV,Sidana S,Go RS,Lacy MQ,Buadi FK,Dingli D,Hayman SR,Kapoor P,Leung N,Fonder A,Hobbs M,Lisa Hwa Y,Gonsalves W,Warsame R,Russell S,Lust JA,Lin Y,Zeldenrust S,Rajkumar SV,Kyle RA,Kum

更新日期：2020-04-01 00:00:00

abstract：:The majority of neutralizing antibodies of HTLV-I are directed against linear epitopes of the envelope surface glycoprotein (gp46) in the immunodominant region 175-199. Although gp46 presents a remarkable degree of conservation, the substitution of the proline at position 192 by a serine is described for 10 isolates a...

journal_title：Leukemia

authors： Londos-Gagliardi D,Armengaud MH,Freund F,Dalibart R,Moze E,Huet S,Legrand E,Guillemain BJ

更新日期：1997-04-01 00:00:00

abstract：:CD13/aminopeptidase N (APN) is a cell surface metallopeptidase expressed by normal and leukemic myeloid cells, and by lymphoblasts in 5-10% of acute lymphoid leukemia (ALL) cases, previously classified as 'biphenotypic' or 'mixed-lineage' leukemias. In fresh cells from two early B-lineage, t(9;22)-positive, ALL cases ...

journal_title：Leukemia

authors： Saito M,Kumagai M,Okazaki T,Nakazawa S,Shapiro LH,Look AT,Campana D

更新日期：1995-09-01 00:00:00

abstract：:Dasatinib treatment markedly increases the number of large granular lymphocytes (LGLs) in a proportion of Ph+ leukemia patients, which associates with a better prognosis. The lymphocytosis is predominantly observed in cytomegalovirus (CMV)-seropositive patients, yet detectable CMV reactivation exists only in a small f...

journal_title：Leukemia

authors： Ishiyama K,Kitawaki T,Sugimoto N,Sozu T,Anzai N,Okada M,Nohgawa M,Hatanaka K,Arima N,Ishikawa T,Tabata S,Onaka T,Oka S,Nakabo Y,Amakawa R,Matsui M,Moriguchi T,Takaori-Kondo A,Kadowaki N

更新日期：2017-01-01 00:00:00

abstract：:The myeloproliferative neoplasms (MPNs) are characterized by hematopoietic stem/progenitor cell (HSPC) expansion and overproduction of mature blood cells. The JAK2V617F mutation is present in hematopoietic cells in a majority of patients with MPNs, but the mechanism(s) responsible for MPN stem cell expansion remain in...

journal_title：Leukemia

authors： Zhan H,Ma Y,Lin CH,Kaushansky K

更新日期：2016-12-01 00:00:00

abstract：:Targeting of B cell receptor associated kinases (BAKs), such as Bruton's tyrosine kinase (BTK) or phosphoinositol-3-kinase (PI3K) delta, by specific inhibitors has revolutionized the therapy of B lymphoid malignancies. BAKs are critical signaling transducers of BCR signaling and seem relevant in B cell lymphoma pathog...

journal_title：Leukemia

authors： Nguyen PH,Niesen E,Hallek M

更新日期：2019-03-01 00:00:00

abstract：:Multiple myeloma (MM) is a plasma cell tumor marked by clonal evolution and preceded by a premalignant stage, which progresses via molecular pathway deregulation, including MYC activation. This activation relates to translocation or gain of the MYC locus and deregulation of upstream pathways such as IRF4, DIS3/LIN28B/...

journal_title：Leukemia

authors： Jovanović KK,Roche-Lestienne C,Ghobrial IM,Facon T,Quesnel B,Manier S

更新日期：2018-06-01 00:00:00

abstract：:We studied the differentiation profiles of B cell precursors (BCP) in normal and post-chemotherapy pediatric bone marrow (BM) using multiparameter flow cytometry. The goal of our study was to draw a comprehensive phenotypic map of the three major maturational BCP stages in BM. By correlating lineage-associated markers...

journal_title：Leukemia

authors： Dworzak MN,Fritsch G,Fleischer C,Printz D,Fröschl G,Buchinger P,Mann G,Gadner H

更新日期：1997-08-01 00:00:00

abstract：:A case of an infant male with Down's syndrome, pancytopenia, and a relative lymphocytosis is presented. A bone marrow aspirate and crushed marrow biopsy were evaluated by microscopy and flow cytometry. A population of immature lymphoid cells positive for CD10 (CALLA) and CD19 (Leu 12) was initially interpreted as sugg...

journal_title：Leukemia

authors： Richard G,Brody J,Sun T

更新日期：1993-11-01 00:00:00

abstract：:These ECOG trials have demonstrated that progressive increments in the intensity of post-remission therapy result in improving long-term, disease-free survival in adults with AML. The median duration of disease-free survival and long-term outcome from different post-remission therapies are summarized in Table 4. [tabl...

journal_title：Leukemia

authors： Cassileth PA,Andersen JW,Bennett JM,Harrington DP,Hines JD,Lazarus HM,Mazza JJ,McGlave PP,O'Connell MJ,Paietta E

更新日期：1992-01-01 00:00:00

abstract：:Current guidelines for smoldering multiple myeloma (SMM) recommend active monitoring until the onset of multiple myeloma (MM) before initiating treatment or enrollment in a clinical trial. Earlier intervention may delay progression to MM. In CENTAURUS, 123 patients with intermediate-risk or high-risk SMM were randomly...

journal_title：Leukemia

authors： Landgren CO,Chari A,Cohen YC,Spencer A,Voorhees P,Estell JA,Sandhu I,Jenner MW,Williams C,Cavo M,van de Donk NWCJ,Beksac M,Moreau P,Goldschmidt H,Kuppens S,Bandekar R,Clemens PL,Neff T,Heuck C,Qi M,Hofmeister CC

更新日期：2020-07-01 00:00:00

abstract：:Analysis at the DNA and RNA level revealed a mature genetic marker profile in a case of T type blast crisis of chronic myelocytic leukemia. T cell receptor beta chain gene rearrangement as well as T cell receptor alpha mRNA transcription was demonstrated in blasts of the malignant clone. Corresponding findings were ob...

journal_title：Leukemia

authors： Valent P,Bartram CR,Radaszkiewicz T,Hinterberger W,Lechner K,Bettelheim P

更新日期：1988-03-01 00:00:00

abstract：:The concept of applying all active therapeutic agents in Total Therapy (TT) clinical trials for newly diagnosed multiple myeloma was pursued with the intent of developing curative treatment. The results of TT1 (n=231), TT2 (n=668) without or with thalidomide and TT3 with added bortezomib (n=303) have been reported. An...

journal_title：Leukemia

authors： Usmani SZ,Crowley J,Hoering A,Mitchell A,Waheed S,Nair B,AlSayed Y,Vanrhee F,Barlogie B

更新日期：2013-01-01 00:00:00

abstract：:Multidrug resistance (MDR), a significant impediment to the successful treatment of cancer clinically, has been attributed to the overexpression of P-glycoprotein (P-gp), a plasma membrane multidrug efflux transporter. P-gp maintains sublethal intracellular drug concentrations by virtue of its drug efflux capacity. Th...

journal_title：Leukemia

authors： Bebawy M,Combes V,Lee E,Jaiswal R,Gong J,Bonhoure A,Grau GE

更新日期：2009-09-01 00:00:00

abstract：:Immunofluorescent staining of peripheral blood mononuclear cells with the monoclonal antibody anti-HC2 combined with phase microscopic examination identified leukemic hairy cells in nine of 13 patients (69%) evaluated at Memorial Hospital prior to treatment with recombinant alpha-interferon (rIFN-alpha A). The remaini...

journal_title：Leukemia

authors： Berman E,Posnett DN

更新日期：1987-04-01 00:00:00

abstract：:Arsenic trioxide (ATO) induces disease remission in acute promyelocytic leukemia (APL) patients, but not in non-APL acute myeloid leukemia (AML) patients. ATO at therapeutic concentrations (1-2 μM) induces APL NB4, but not non-APL HL-60, cells to undergo apoptosis through the mitochondrial pathway. The role of antiapo...

journal_title：Leukemia

authors： Wang R,Xia L,Gabrilove J,Waxman S,Jing Y

更新日期：2013-02-01 00:00:00

abstract：:Patients with hairy cell leukemia (HCL) are prone to opportunistic infections, which suggests an impaired T-cell functioning. To investigate a possible mechanism of such an impairment, we determined the numbers of naive and memory T cells by measuring the expression of CD45R0 on CD4+ and CD8+ T cells in 23 HCL patient...

journal_title：Leukemia

authors： van der Horst FA,van der Marel A,den Ottolander GJ,Kluin-Nelemans HC

更新日期：1993-01-01 00:00:00

abstract：:The aim was to determine the efficacy and safety of decitabine in the settings of relapse post-allogeneic progenitor cell transplantation or as part of the conditioning regimen. Three patients (two AML, one ALL) received single agent decitabine 1000 mg/m2 total dose) for treatment of relapse post-transplant (group 1)....

journal_title：Leukemia

authors： Giralt S,Davis M,O'Brien S,van Besien K,Champlin R,de Vos D,Kantarjian H

更新日期：1997-03-01 00:00:00